

December 16, 2022

Dear Colleagues,

Two decades ago, I was visiting Japan in late November. It was impossible not to notice the lavish Christmas decorations. What was notable was that it was a full month before Christmas and Japan is largely a non-Christian country. I asked one of my hosts about the red and green ornaments and snowy Christmas scenes and was informed that in Japan they like to celebrate ALL holidays. The concept stuck with me.

Now in the middle of December, we have many holiday choices. Whatever holidays you officially celebrate—none, one, or more—this is a time to take a little time off, relax, smile more easily, and spend time with those you love. It is also a time to be reflective and whenever possible, to be grateful.

Personally, as I have said before, I am enormously grateful for Nancy's and my move to New Haven, for the great potential we have at Yale, and for my colleagues. I was recently at the San Antonio Breast Cancer Symposium with many of my former mentees and colleagues. While I enjoyed seeing them and they will remain a part of my life, I realized that I have a new home and a remarkable group of colleagues and friends to work with, to support, and to enjoy.

Thank you for all that you do every day. Having a mission in life is critical, and whether your passion is clinical care, research, administration, education, or some combination, what you do brings us closer to a time when cancer is no longer a burden on individuals and for our society. Please rejoice in what you do for Yale, for our patients, for research, for each other, and for our future.

Happy Holidays! I look forward to the New Year with great optimism.

Eric

Announcements

Dean Brown to Present State of the School on Tuesday

Please join us on Tuesday, December 20 at noon in the Park Street Auditorium at 55 Park Street for a presentation by Nancy Brown, MD, Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long

Professor of Internal Medicine, on the **State of the School**. Please send questions for Dean Brown in advance by email to

Eric P. Winer, MD

Director, Yale Cancer Center

Physician-in-Chief, Smilow Cancer Network


Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center



Why Some Lung Tumors Respond Better to Targeted Therapies Than Others




[Read More](#)

Opinion: The Deadly Consequences for

questions for Dean Brown in advance by email to canceranswers@yale.edu. There will also be an opportunity to ask questions during the program.

Rong Fan, PhD, Appointed the Harold D. Hodgkinson Professor of Biomedical Engineering

We are pleased to announce Rong Fan, PhD, a member of the Yale Cancer Center Cancer Signaling Networks Research Programs, has been appointed the Harold D. Hodgkinson Professor of Biomedical Engineering at Yale University. Dr. Fan has led research making significant contributions to biotechnology innovation and precision medicine, particularly in the field of single-cell & spatial omics and cancer immunotherapy. He is also a Professor of Pathology at Yale School of Medicine.



Since joining Yale in 2010, Dr. Fan has invented multiple innovative and transformative technologies in single-cell and spatial omics analysis and demonstrated a unique talent for inventing new technologies to advance human genomics and precision medicine. His inventions have led to the creation of three companies. In addition, Dr. Fan is an enthusiastic and valued mentor to young inventors. His graduate students and postdocs are frequently co-inventors on patent applications. He received a BS and MS from the University of Science and Technology of China, and his PhD from the University of California, Berkeley.


Steven H. Kleinstejn, PhD, Appointed Anthony N. Brady Professor of Pathology

Congratulations to Dr. Steven H. Kleinstejn, a member of Yale Cancer Center's Cancer Immunology Research Program, on his appointment as the Anthony N. Brady Professor of Pathology. Dr. Kleinstejn has made fundamental contributions to immunology through the development and application of innovative computational methods. He also serves as co-director of graduate studies for the Program in Computational Biology and Bioinformatics.




A longstanding focus of Dr. Kleinstejn's work has been somatic hypermutation (SHM) and B cell affinity maturation, the core of adaptive immunity. His lab developed the widely used Immcantation framework, which is based on foundational computational methods he devised, including the identification of clonally related B cells, integration of the resulting lineages, detection of immune selection, and inference of migration/differentiation networks. Dr. Kleinstejn has applied these methods in collaborative studies to gain important biological insights into human infection, vaccination, and autoimmunity. He completed his PhD in computer science at Princeton

Black Patients of Blaming the Victim




[Read More](#)

With Discovery, Oxygen's Role in Growth of Tumors Reconsidered




[Read More](#)

Gene Therapy May be Equitable Therapeutic Option for Sickle Cell Disease in US



[Read More](#)

Transforming Cancer Care Through the Microbiome



University and joined the faculty of the Department of Pathology in 2006; he has a secondary appointment in the Department of Immunobiology.

Notables

Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology, Vice Chair for Translational Research, Therapeutic Radiology, and Scientific Director, Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, has been named the **2022 BioCT Entrepreneur of the Year**. The Entrepreneur of the Year award was established by BioCT to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut community whose accomplishments are also having impact beyond the borders of the state.

Edward Perry, Jr., MD, Assistant Professor of Medicine (Medical Oncology), recently presented the keynote lecture on “Schwartz Rounds at VA Connecticut Healthcare System” at the **Association of VA Hematology/Oncology Annual Meeting** in San Diego.

Laura J. Morrison, MD, Associate Professor of Medicine (Geriatrics), Director of Palliative Medicine Education, and Director, Yale Hospice and Palliative Medicine Fellowship, was invited to participate as Core Faculty for the TalkVermont Advanced Goals of Care Communication Skills Course in Burlington, Vermont. This new, innovative course was designed specifically for palliative care physician and APRN fellows from University of Vermont, Dartmouth, Maine Medical, and Yale to train together in advanced serious illness communication simulation scenarios.

Mathieu Bakhom, MD, PhD, Assistant Professor of Ophthalmology & Visual Science, has received a grant from the Connecticut Lions Eye Research Foundation (CLERF). The funding will support his laboratory's efforts to develop non-invasive biomarkers for uveal melanoma, the most common intraocular cancer in adults.


Bayan Galal '23, a pre-med student double majoring in molecular, cellular, and developmental biology and global affairs studying in the laboratory of Daniel DiMaio, MD, PhD, has been named a **Marshall Scholar**, one of only 40 in the country. Marshall Scholarships fund up to three years of graduate study in the United Kingdom for Americans poised to become leaders in their fields.

Diversity, Equity, and Inclusion

First-Generation Low-Income Faculty Mentors

We are seeking self-identified first-generation low-income (FGLI) faculty members at Yale School of Medicine who are interested in receiving and/or providing medical career mentorship.

First-generation low-income (FGLI) individuals in medicine are believed to encounter a unique set of obstacles to their career progression. In an effort to create community, and provide support, networking, and mentoring opportunities, we are reaching out to assess interest in a Yale FGLI



[Read More](#)

Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile



[Read More](#)

Kirstie Alley and Colon Cancer: The Early Signs You Shouldn't Ignore



[Read More](#)

Trastuzumab Deruxtecan Generates PFS, OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast

Mentorship Program among our Yale School of Medicine faculty.

Who are first-generation low-income individuals in medicine?

- A "first-generation" individual in medicine is a physician whose parents have not attended or graduated from college thus making them among the first generation in their family to earn a bachelor's degree, or a physician who is a first-generation American or an immigrant to the United States.
- An individual in medicine who was formerly a "low-income student" is a physician who identifies with having been raised in a low socioeconomic environment. It is sometimes defined in higher education forums by Pell Grant eligibility as an undergraduate student and/or U.S. Department of Health and Human Services Scholarship for Disadvantaged Students eligibility as a medical student.
- Individuals in medicine who are formerly "first-generation low-income (FGLI) students" are physicians who identify with having been either or both a "first-generation" and/or "low-income" student.

If you are interested in learning more about receiving or providing mentorship as a FGLI faculty member, please complete a **brief survey**. If you do not identify as a FGLI faculty member but would like to mentor FGLI individuals in medicine, please also complete the survey and indicate so. We will then be in touch with additional information.

Expanded Fertility Benefits at Yale

As of 2023, fertility benefits for Yale faculty and non-union employees who are enrolled in Aetna or Yale Health medical benefits will expand to single individuals and those with single-sex partners. Additionally, a surrogacy benefit (\$10K toward authorized costs) is available to any benefit-eligible employee. While there is still work to be done to advocate for fertility benefits for all members of the Yale University community, this is positive progress. Please review your individual benefits and reach out to your plan contact for more information.

Employee Profile: Barbara Lumpkin

After over 30 years at Yale, Barbara Lumpkin, Senior Administrative Assistant for Yale Cancer Center, will retire as of next week. Barbara started as part of the former Cancer Information



Service (CIS), a cancer communication network for the National Cancer Institute, but moved to the Section of Hematology where she was supporting five faculty/clinicians.

In between her daily tasks of scheduling meetings, submitting expense reports, and making travel arrangements, Barbara has grown a great appreciation for the dedication and commitment it takes to manage both the

Cancer



[Read More](#)

Follow us!

facebook



YouTube

Instagram



appreciation for the dedication and commitment it takes to manage both the clinical and academic responsibilities that her faculty take on, and has been honored to play a role in assisting with that. "There is so much work done outside of the clinic that people don't realize. They are required to take certain classes, give lectures, and stay up to date on the latest advances. I am so proud to have been a part of this organization for so long, and to support these doctors that are making a difference."

Richard Carr, Administrative Supervisor for the Section of Hematology, commented, "Yale Cancer Center has been fortunate to have Barbara's support now for 32 years. She has worked with kindness, dedication, and as a team player. I am especially appreciative of her work this past year, having continued supporting hematology until a replacement could be found, and then filling in where there was need these last months. I am truly grateful to her for staying on with us for a little longer."

Alfred Lee, MD, PhD, Associate Professor of Medicine (Hematology), commented, "Barbara has been my administrative assistant since I started at Yale and she first helped me get settled. Since then, she's been with me every step of the way, helping me out academically, administratively, and even emotionally. She is one of the dearest people in my life and has become family to me. I will miss her support greatly."

Thank you to Barbara. We send her congratulations, appreciation, and best wishes on her next chapter.

Recent Publications

Agashe, R. P., Lippman, S. M., & Kurzrock, R.
JAK: Not Just Another Kinase.
Molecular cancer therapeutics, 21(12), 1757–1764.
[Read More](#)

Yan, H., Talty, R., & Johnson, C. H.
Targeting ferroptosis to treat colorectal cancer.
Trends in cell biology, S0962-8924(22)00254-9.
[Read More](#)

Shabbir, A., Kojadinovic, A., Shafiq, T., & Mundi, P. S.
Targeting RET alterations in cancer: Recent progress and future directions.
Critical reviews in oncology/hematology, 103882.
[Read More](#)

Goshua, G., Bendapudi, P. K., & Lee, A. I.
Thrombosis questions from the inpatient wards.
Hematology. American Society of Hematology. Education Program, 2022 (1), 481–490.
[Read More](#)


Park, H. A., Brown, S. R., Jansen, J., Dunn, T., Scott, M., Mnatsakanyan, N., Jonas, E. A., & Kim, Y.
Fluid shear stress enhances proliferation of breast cancer cells via downregulation of the c-subunit of the F1FO ATP synthase.

The Fall | Winter 2022 issue of Centerpoint Magazine, a bi-annual publication from Yale Cancer Center and Smilow Cancer Hospital, is now available online! Read about the latest research and clinical advances for our patients, and how we have invested in expanding our Sickle Cell Program and clinical cancer genetics.



[Read More](#)

Meet Eric Winer, MD, Director of Yale Cancer Center, and Physician-in-Chief of the Smilow Cancer Network. "I am grateful for the opportunity to lead Yale Cancer Center and the Smilow Network to advance cancer research, identify new and better therapies for the future, and provide the best possible care to our patients today. I am humbled by the strength of our patients and the remarkable work of my colleagues."



"I am grateful for the opportunity to lead Yale Cancer Center and the Smilow Network to advance cancer research, identify new and better therapies for the future, and provide the best possible care to our patients today. I am humbled by the strength of our patients and the remarkable work of my colleagues."

- Eric Winer, MD, Director of Yale Cancer Center, and Physician-in-Chief

Read More

Gaffey, A. E., Han, L., Ramsey, C. M., Skanderson, M., Dziura, J., Driscoll, M., Burg, M. M., Brandt, C. A., Bastian, L. A., & Haskell, S. G.

Post-9/11 deployment history and the incidence of breast cancer among women Veterans.

Annals of epidemiology, S1047-2797(22)00303-9.

Read More

Owusu, K. A., Schiffer, M., & Perreault, S.

Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations.

AACN advanced critical care, 33(4), 301–307.

Read More

Mandell, J. D., Cannataro, V. L., & Townsend, J. P.

Estimation of neutral mutation rates and quantification of somatic variant selection using canceffectsizer.

Cancer research, CAN-22-1508.

Read More

Josowitz, A. D., Bindra, R. S., & Saltzman, W. M.

Polymer nanocarriers for targeted local delivery of agents in treating brain tumors.

Nanotechnology, 34(7), 10.1088/1361-6528/ac9683.

Read More

Herbst, R. S., Hatsukami, D., Acton, D., Giuliani, M., Moushey, A., Phillips, J., Sherwood, S., Toll, B. A., Viswanath, K., Warren, N. J. H., Warren, G. W., & Alberg, A. J.

Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology.

Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(35), 4144–4155.

Read More

Adua, S. J., Arnal-Estapé, A., Zhao, M., Qi, B., Liu, Z. Z., Kravitz, C., Hulme, H., Strittmatter, N., López-Giráldez, F., Chande, S., Albert, A. E., Melnick, M. A., Hu, B., Politi, K., Chiang, V., Colclough, N., Goodwin, R. J. A., Cross, D., Smith, P., & Nguyen, D. X.

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.

Nature communications, 13(1), 7690.

Read More

Santana, J. G., Shewarega, A., Nam, D., Kahl, V., Madoff, D. C., Zhang, X., & Chapiro, J.

Experimental VX2 rabbit liver tumor model in carbon tetrachloride-induced cirrhosis of the liver.

Journal of vascular and interventional radiology : JVIR, S1051-0443(22)01388-4.

Read More

Chen, Q., Lu, L., & Ma, W.

Read More

As the new director of the Sickle Cell Program at Smilow Cancer Hospital, Cecelia “Cece” Calhoun, MD, MPH, MBA, strives to ease the suffering and burden of sickle cell warriors and advance their care options by building on the program’s strong foundation and rallying the tremendous resources of Yale; but most importantly, the knowledge of the community.



Read More

Recently on Yale Cancer Answers, our new Chief of Surgical Oncology at Smilow Cancer Hospital and Yale Cancer Center, Dr. Kiran Turaga, discussed innovations in the treatment of metastatic cancers. Listen on Connecticut Public Radio or download our podcast from iTunes.



Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.

Cancers, 14(23), 5983.

[Read More](#)

Heumann, T. R., Baretta, M., Sugar, E. A., Durham, J. N., Linden, S., Lopez-Vidal, T. Y., Leatherman, J., Cope, L., Sharma, A., Weekes, C. D., O'Dwyer, P. J., Reiss, K. A., Monga, D. K., Ahuja, N., & Azad, N. S.

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.

Clinical epigenetics, 14(1), 166.

[Read More](#)

Lander, E. M., Rappazzo, K. C., Huang, L. C., Hu, J. R., Chen, H., Shyr, Y., & Abramson, V. G.

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.

The oncologist, oyac247.

[Read More](#)

Lee, H. Y., Jang, H. R., Li, H., Samuel, V. T., Dudek, K. D., Osipovich, A. B., Magnuson, M. A., Sklar, J., & Shulman, G. I.

Deletion of Jazf1 gene causes early growth retardation and insulin resistance in mice.

Proceedings of the National Academy of Sciences of the United States of America, 119(49), e2213628119.

[Read More](#)

Patel, C. H., Heikamp, E. B., Xu, W., Sun, I. H., Oh, M. H., Sun, I. M., Wen, J., Tam, A. J., Blosser, R. L., & Powell, J. D.

Cutting Edge: mTORC2 Regulates CD8+ Effector and Memory T Cell Differentiation through Serum and Glucocorticoid Kinase 1.

Journal of immunology (Baltimore, Md. : 1950), 209(12), 2287–2291.

[Read More](#)

Rahman, S. N., Lokeshwar, S. D., Syed, J. S., Javier-Desloges, J. F., Press, B. H., Choksi, A. U., Rajwa, P., Pradere, B., Ploussard, G., Kim, J. W., Monaghan, T. F., Renzulli, J. R., Shariat, S. F., & Leapman, M. S.

Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder.

Urologic oncology, S1078-1439(22)00317-9.

[Read More](#)

Rodriguez, C. P., Kang, H., Geiger, J. L., Burtness, B., Chung, C. H., Pickering, C. R., Fakhry, C., Le, Q. T., Yom, S. S., Galloway, T. J., Golemis, E., Li, A., Shoop, J., Wong, S., Mehra, R., Skinner, H., Saba, N. F., Flores, E. R., Myers, J. N., Ford, J. M., ... Malik, S.

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Journal of the National Cancer Institute, 114(12), 1619–1627.


[Read More](#)

Bewersdorf, J. P., Patel, K. K., Goshua, G., Shallis, R. M., Podoltsev, N. A., Stahl, M., Stein, E. M., Huntington, S. F., & Zeidan, A. M.

Cost effectiveness of azacitidine and iposideritin in newly diagnosed

[Read More](#)

Meet Mehra Golshan, MD, MBA, Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Executive Vice Chair of Surgery. "I am grateful for the privilege of working with an amazing team of nurses, staff, advanced practice providers, physicians in the care of our cancer patients across the state of CT and beyond. Yale Cancer Center/Smilow provides a lifeline during a patient and their families most desperate hour, something that we never forget day in and day out."



[Read More](#)

The Lustgarten Foundation announced Mandar Muzumdar, MD, Assistant Professor of Genetics and of Medicine (Medical Oncology), as the recipient of a 2022 Innovation and Collaboration Program Grant. The funding will support his study titled "Dietary oleic acid reprograms pancreatic lipid metabolism to drive cancer development."

Congratulations, Dr. Muzumdar!



Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.

Leukemia & lymphoma, 1–8.

[Read More](#)

Cassidy, R. N., Tidey, J. W., Jackson, K. M., Cioe, P. A., Murphy, S. E., Krishnan-Sarin, S., Hatsukami, D., & Colby, S. M.

The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results from a Randomized Controlled Trial.

Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco, ntac279.

[Read More](#)

Invasion working group, Thunnissen, E., Beasley, M. B., Borczuk, A., Dacic, S., Kerr, K. M., Minami, Y., Nicholson, A. G., Sholl, L., Tsao, M. S., Noguchi, M., Lissenberg-Witte, B., Le Quesne, J., Roden, A. C., Chung, J. H., Yoshida, A., Moreira, A. L., Lantuejoul, S., Pelosi, G., Poleri, C., ... Cooper, W.

Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee.

Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, S1556-0864(22)01936-0.

[Read More](#)

Bold, K., O'Malley, S., Krishnan-Sarin, S., & Morean, M.

E-cigarette use patterns, flavors, and device characteristics associated with quitting smoking among a US sample of adults using e-cigarettes in a smoking cessation attempt.

Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco, ntac276.

[Read More](#)

Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Necchi, A., Petrylak, D. P., Plimack, E. R., Xu, J. Z., Imai, K., Moreno, B. H., Bellmunt, J., de Wit, R., & O'Donnell, P. H.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology: official journal of the European Society for Medical Oncology, S0923-7534(22)04760-3.

[Read More](#)

Wu, J., Liu, Z., Huang, T., Wang, Y., Song, M. M., Song, T., Long, G., Zhang, X., Li, X., & Zhang, L.

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. *Molecular oncology*, 10.1002/1878-0261.13357.

[Read More](#)

Xi, Q., Meza, R., Leventhal, A., & Tam, J.

Modeling cigarette smoking disparities between people with and without serious psychological distress in the US, 1997-2100.

Preventive medicine, 107385.

[Read More](#)

[Read More](#)

Veda N. Giri, MD, the new Chief of the Division of Clinical Cancer Genetics at Smilow Cancer Hospital and Yale Cancer Center, sees the intersection of genetic testing, clinical care, and population science as the future of cancer genetics. Dr. Giri looks forward to working with the team at Yale to create a world-class clinical cancer genetics program.



[Read More](#)

Meet Jayanti, breast cancer survivor. "I am grateful that I am here to be an advocate for others facing the difficult journey of cancer and hope my story can help them along the way."



[Read More](#)

Udoh, M. O., Mian, Z., Anakwenze, L., Okeke, C., Ziegler, C., & Sawning, S. **Grow502: Centering Community in Medical Education via a Student-Created Organization Focused on Cultivating a Healthy Community.** *Health promotion practice, 15248399221136533.*

[Read More](#)

O'Toole, D., Kunz, P. L., Webb, S. M., Goldstein, G., Khawaja, S., McDonnell, M., Boiziau, S., Gueguen, D., Houchard, A., Ribeiro-Oliveira, A., Jr, & Prebtani, A.

PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.

Advances in therapy, 1–20.

[Read More](#)

Barrios, O., Sánchez, B. G., Rodríguez-Prieto, T., Cano, J., Bort, A., Gómez, R., & Díaz-Laviada, I.

Alteration of the HIF-1 α /VEGF Signaling Pathway and Disruption of the Cell Cycle by Second Generation Carbosilan Dendrimers.

Biomacromolecules, 23(12), 5043–5055.

[Read More](#)

Jaber Chehayeb, R., Hood, A., Wang, X., Miksad, R., Schellhorn Mougalian, S., Lustberg, M. B., Wang, S. Y., Greenup, R. A., Pusztai, L., & Kunst, N.

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.

JAMA network open, 5(11), e2244204.

[Read More](#)

Funding and Award Opportunities

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)

Through this FOA, the NCI invites P20 planning grant applications for developing collaborative partnerships between institutions serving health disparity populations and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer

research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.

Application Deadline: January 6, 2023

[Read More](#)

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students and NCI-designated Cancer Centers. The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education



@DrRoyHerbstYale @politikaterina @MJGrantMD provide insight

#ASCODailyNews on the Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer



Bruce McGibbon, MD, received the 2022 #NormRothLeadershipAward

from Greenwich Hospital @GreenHosp, given by the Medical Staff in appreciation for his service and in recognition of emerging leaders at the hospital. Congratulations!



A study from @DrParisButler & Dr. Jackie Oh @YalePlastics examines

how disparities manifest at multiple junctures of #breastcancer care, including access, and how these disparities can be mitigated.



In a study presented at #ASH22, @GeorgeGoshuaMD shared how

gene therapy for patients with #SickleCell disease was found to be cost-effective when #healthdisparities are considered.



Michael Cecchini, MD, @Cecchini_OncMD has been

appointed to the Colon Task Force of the NCI Gastrointestinal Steering Committee for a 2-year term as an early career investigator.



.@BraunMDPhD discusses immune checkpoint inhibitors for

#kidneycancer and why not all patients benefit. “We start with the patient and learn from their tumor, always with the goal of improving diagnostics and therapeutics.”



Meet Stephanie Halene, MD, Chief of @YaleHematology . “I am grateful for having the opportunity to work

with the most wonderful professionals in everything we do.”



Today at noon, Dr. David Braun @BraunMDPhD, Assistant

Professor of Medicine @yalepathology @Yale_Urology will present #GrandRounds on anti-tumor immunity in #kidneycancer. Please join us in person or via Zoom. <http://bit.ly/3VTgkU3>

and address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer's impact on underserved populations.

Application Deadline: January 6, 2023

Read More

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)

Through this FOA, the NCI invites P20 planning grant applications for developing collaborative partnerships between institutions serving health disparity populations and underrepresented students (ISUPs) and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.

Application Deadline: January 6, 2023

Read More

DeLuca Pilot Award

5 pilot awards will be awarded to support investigators pursuing research in Hematology and to generate preliminary data for new NCI/NIH grant applications. The research should seek to advance our knowledge in Hematologic disorders and to improve patient care, therapies, and outcomes. For more information, please contact Richard.Carr@yale.edu

Letter of Intent Due: January 9, 2023

Read More

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01/U24)

The purpose of this FOA is to solicit applications for Liquid Biopsy Research Laboratories (LBRLs), one of the two components of the Precompetitive Collaboration on Liquid Biopsy for Early-Cancer Assessment Consortium (LBC). The LBRLs will conduct research on the development of liquid biopsy technologies, assays and/or methods for the capture and analysis of tumor associated cells, DNA, RNA, or exosomes in body fluids of individuals with early-stage cancer or at high risk of developing the disease.

Application Deadline: January 10, 2023

Read More

CRI Lloyd J. Old STAR Program

The CRI Lloyd J. Old STAR Program—Scientists TAKing Risks—provides long-term funding to mid-career scientists, giving them the freedom and flexibility to pursue high-risk, high-reward research at the forefront of discovery and innovation in cancer immunotherapy.

Deadline for Applications: January 15, 2023

Read More

Breast Cancer Research Foundation Precision Prevention Initiative

The overarching goal of the 2023 BCRF Precision Prevention Initiative is to fuel innovation and accelerate breast cancer prevention research by challenging the research community to think boldly; to explore multidisciplinary approaches to get the answers in less time, utilize new technologies or identify new ways to examine available data, and to build or enhance infrastructure, resources, and tools that will facilitate innovation in prevention research for years to come.

Letter of Intent Due: January 16, 2023

Read More



At 6pm CST, Dr. Jan Philipp

Bewersdorf presents research

#ASH22 with Dr. Amer Zeidan

@Dr_AmerZeidan on TP-53 mutations in

patients with Acute Myeloid Leukemia #AML

and Higher Risk Myelodysplastic Syndromes

(HR-#MDS).



Dr. Rong Fan @RongFan8 presents

during the #ASH22 Scientific

Program at 2:45pm CST on the emerging

technologies developed in his lab for

spatially resolved genome-wide tissue

profiling at the cellular level via DBiT.



Dr. George Goshua

@GeorgeGoshuaMD will provide a

briefing on #sicklecelldisease during the

#ASH22 Annual Meeting Press Program

today at 12pm CST, with the full presentation

at 3:15pm.



At 10:30am CST #ASH22, Dr.

George Goshua GeorgeGoshuaMD

will participate in a Spotlight Session Debate,

representing the 'Against' opinion on whether

'most/all patients with Acquired TTP should

receive caplacizumab.'



As the new director of the

#SickleCell Program at

@SmilowCancer, Cecelia "Cece" Calhoun,

MD, MPHS, MBA @cececalhounMD, strives

to ease patients' suffering & burden, while

educating the community.



Congratulations to Barbara

Burtness, MD, who was appointed

Chief Translational Research Officer for Yale

Cancer Center and Smilow Cancer Hospital

@SmilowCancer, and Associate Cancer

Center Director for Translational Research

for Yale Cancer Center.

Calendar

Yale Cancer Answers

December 18; 7:30 PM

Physical Therapy Support for Patients

Scott Capozza, PT, MS, and Suzanne

Burbank, PT

Learn More

Yale Cancer Center Special Seminar

Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01)

The purpose of this FOA is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.

Application Deadline: February 5, 2023

[Read More](#)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01)

This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups are encouraged to work with their institutions to apply.

Application Deadline: February 6, 2024

[Read More](#)

Transformative Educational Advancement and Mentoring Network (TEAM) (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

Application Deadline: February 10, 2023

[Read More](#)

2023 K12 Immuno-Oncology Training Program (IOTP) Scholar Award

YCC-IOTP Scholar Award is an award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training. Successful applicants are required to demonstrate a strong commitment to a career in cancer immunology. The two-year IOTP curriculum includes didactic and practical training in basic, translational and clinical aspects of cancer

immunology research. The program also includes a required research component (either clinical or bench research, or a combination thereof).

Applicants are required to identify a mentor and provide a research and mentorship proposal.

Full Application Due: February 15, 2023

[Read More](#)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01)

The purpose of this FOA is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.

Application Deadline: February 21, 2023

[Read More](#)

December 20; 9:30 AM

Cancer Immunotherapy in Modern Medicine - Immune Check Point Inhibitor Related Gastrointestinal Toxicities and Future Directives

Binny Khandakar

[Learn More](#)

Yale Cancer Center Grand Rounds

December 20; 12:00 PM

55 Park Street; Auditorium

State of the School

Nancy J. Brown, MD

[Learn More](#)

Cancer Genetics and Prevention Program Seminar

December 22; 2:30 PM

[Learn More](#)

Yale Cancer Answers

December 25; 7:30 PM

Theranostics and clinical trials for GI Cancers

Gabriela Zagarodone Spilberg Missine, MD

[Learn More](#)

Yale Cancer Answers

January 1; 7:30 PM

Racial Disparities and Cancer and Improving Health Outcomes

Jacquelyne Gaddy, MD

[Learn More](#)



Share your news!

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00)

The purpose of this FOA is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.

Application Deadline: February 21, 2023

Read More

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025

This FOA supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Application Deadline: February 22, 2023

Read More

NCI Cancer Screening Research Network Funding Opportunities

The CSRN conducts rigorous, multi-center cancer screening trials and studies with large and diverse populations in a variety of health care settings with the goal of reducing cancer incidence and cancer-related morbidity and mortality. Cancer screening provides a unique opportunity to diagnose cancers and pre-cancerous lesions before symptoms develop.

- **ACCruel, Enrollment, and Screening Sites (ACCESS) Hub (UG1)**

Read More

- **Statistics and Data Management Center (UG1)**

Read More

- **Coordinating and Communication Center (UG1)**

Read More

Application Deadlines: February 28, 2023

JH Milstone Fund Grant

JH Milstone Fund will award a grant in 2023 to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important. For more information, please contact Richard.Carr@yale.edu

Letter of Intent Due: March 1, 2023

Read More

DeLuca Career Development Award

The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the goal to achieve independent support for their research from a national agency. For more information, please contact Richard.Carr@yale.edu

Letter of Intent Due: March 1, 2023

Read More

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61)

Clinical Cancer Research (R01)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Application Deadline: March 1, 2023

Read More

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This FOA invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

Application Deadline: March 1, 2023

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Deadline: March 1, 2023

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Application Deadline: March 1, 2023

Read More

YCCI Educational Funding Support Opportunities

- **YCCI Scholar Awards and Yale Physician-Scientist Development Awards:** provide salary and/or research funds to a select number of junior faculty members who are strongly committed to research careers focused on improving human health.

Letters of Intent Due: January 6, 2023

Read More

- **YCCI Multidisciplinary Post-Doctoral Training Program in Translational Research:** provide an opportunity for Yale post-doctoral trainees in the Schools of Medicine, Nursing, Public Health, Engineering and Applied Science or other appropriate Departments in the Graduate School to receive up to 2 years devoted to training across the full span of clinical and translational research focused on human health.

Application Deadline: March 10, 2023

Read More

- **YCCI Multidisciplinary Pre-Doctoral Training Program in Translational Research:** aims to identify and support a representative and diverse group of outstanding trainees who specifically want to pursue careers in clinical and translational research; to train them in the use of state-of-the-art research tools; to enhance their abilities to work collaboratively in complex multidisciplinary research teams; to provide outstanding mentoring (including concordant mentoring) by experienced and diverse faculty that support the trainee's long-term professional development.

Application Deadline: March 10, 2023

Read More

AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01)

The goal of this FOA is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This initiative will encourage development, evaluation, and validation of biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early HNC.

Application Deadline: March 14, 2023

Read More

Diversity and Inclusion in Breast Cancer Research

The following research awards are designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. These awards are made possible through the support of the Breast Cancer Research Foundation (BCRF).

- **Career Development Award:** Full Application Due: March 13, 2023

Read More

- **Young Investigator Award:** Full Application Due: March 13, 2023

Read More

Joint SPORE Developmental Research Program (DRP) Award – Cancer Disparities

The YCC Translational Research Office in collaboration with the Yale SPORE in Lung Cancer (YSILC) and the Yale Head and Neck SPORE (YHN-SPORE) have launched a new DRP award to provide support up to \$50,000 for a translational pilot project focused on **disparities-related cancer research** in the field of Head and Neck and/or Lung cancer. Studies with a strong translational or clinical component that have the potential to evolve into, or be incorporated into, a full SPORE project and projects with multi-disciplinary collaborations and/or community-based participatory research studies are encouraged.

We encourage to submit your letter of intent (LOI) to anna.arnal@yale.edu

There is no deadline to apply, LOIs will be reviewed and eligible applicants will be invited to submit a full application online

at: <https://yale.infoready4.com/>

Read More

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

[Unsubscribe renee.gaudette@yale.edu](#)

[Update Profile](#) | [Constant Contact Data
Notice](#)

Sent by renee.gaudette@yale.edu powered by



Try email marketing for free today!